Alnylam Pharmaceuticals Inc Stock Price, News & Analysis

Alnylam Pharmaceuticals (ALNY), a leader in RNAi therapeutics, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will deliver a corporate presentation on June 9, 2025, at 9:20 am ET. Investors and interested parties can access a live audio webcast through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available within 48 hours after the event.

Alnylam Pharmaceuticals (NASDAQ: ALNY) has released its 2024 Corporate Responsibility Report, focusing on "Accepting Challenges to Improve the Health of Humanity." The report showcases significant progress across six corporate responsibility pillars, highlighting environmental stewardship, patient access, and health equity initiatives.

Key achievements include: independently verified data on GHG emissions (Scope 1, 2, and 3), implementation of 100% renewable energy at Norton and Alewife manufacturing sites, advancement of their Patient Access Philosophy, and expansion of the Alnylam Challengers global health equity initiative. The company's culture survey revealed strong employee satisfaction, with 88% of employees feeling accepted and treated fairly.

Alnylam Pharmaceuticals (ALNY) presented compelling new data from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran) for treating ATTR amyloidosis with cardiomyopathy at Heart Failure 2025 Congress. The analysis showed significant reductions in mortality and cardiovascular events: - 36% reduction in all-cause mortality risk through 42 months - 33% reduction in cardiovascular mortality risk - 46% reduction in urgent heart failure visits - 33% reduction in heart failure hospitalizations - 27% reduction in cardiovascular events - 25% reduction in cardiovascular hospitalizations The results were simultaneously published in JACC, with vital status confirmed for over 99% of patients. AMVUTTRA has received FDA and ANVISA approval for ATTR-CM treatment, with EMA approval expected by Q3 2025. The company also announced plans for TRITON-CM, a Phase 3 study of their next-generation RNAi therapeutic nucresiran.

Alnylam Pharmaceuticals (NASDAQ: ALNY) will present new data from its TTR amyloidosis franchise at the Heart Failure 2025 Congress in Belgrade. Key highlights include additional analyses of the HELIOS-B Phase 3 study of vutrisiran in ATTR-CM patients, featuring extended 42-month data on cardiovascular outcomes. The presentation follows recent AMVUTTRA® (vutrisiran) approvals in the U.S. and Brazil for treating cardiomyopathy in adults with wild-type or hereditary transthyretin-mediated amyloidosis, along with a positive CHMP opinion in Europe. The congress will also showcase the TRITON-CM Phase 3 study design for nucresiran (ALN-TTRsc04) and analysis of vutrisiran's effectiveness in patients who progressed on tafamidis treatment.

Alnylam Pharmaceuticals (ALNY), a leader in RNAi therapeutics, has announced its upcoming presentation at the BofA Securities 2025 Health Care Conference. The company's management will deliver a corporate overview on Wednesday, May 14, 2025, at 11:20 AM PT (2:20 PM ET). Investors and interested parties can access a live audio webcast of the presentation through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available on the company's website within 48 hours after the event.

Alnylam Pharmaceuticals (ALNY) has received a positive CHMP opinion recommending approval of vutrisiran for treating ATTR amyloidosis with cardiomyopathy (ATTR-CM) in the EU. This recommendation is based on the successful HELIOS-B Phase 3 study, which met all 10 pre-specified endpoints.

Vutrisiran, marketed as AMVUTTRA®, demonstrated significant reductions in mortality and cardiovascular events while maintaining functional status and quality of life. The treatment offers quarterly subcutaneous dosing and has already received approvals in the U.S. and Brazil in March 2025.

The study showed consistent benefits across all patient subgroups, including those on TTR stabilizers. Safety profile was comparable to placebo, with main reactions including injection site reactions and increases in blood alkaline phosphatase. European Commission's final decision is expected in June 2025.

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has scheduled its first quarter 2025 financial results announcement for Thursday, May 1, 2025, before U.S. markets open. The company will host a conference call at 8:30 am ET the same day, where management will discuss Q1 2025 performance and future outlook. A live audio webcast will be accessible through the Investors section of Alnylam's website, with an archived version available approximately two hours after the event.

Alnylam Pharmaceuticals (Nasdaq: ALNY), a leader in RNAi therapeutics, has announced its upcoming participation in the Needham 24th Annual Virtual Healthcare Conference. The company's management will deliver a corporate overview presentation on Tuesday, April 8, 2025, at 11:45 am ET.

Interested parties can access a live audio webcast of the presentation through the Investors section of Alnylam's website at www.alnylam.com/events. A replay of the presentation will be made available on the company's website within 48 hours following the event.